ARCH
2017
Active-controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk
In 4,093 postmenopausal women with high fracture risk, romosozumab followed by alendronate reduced new vertebral, clinical and hip fractures compared with alendronate alone.
Result
Primary endpoint: New vertebral fracture
Vertebral fracture −48 %; clinical fracture −27 %; hip fracture −38 %. Excess serious CV events in the romosozumab arm (2.5 % vs 1.9 %).
- Subtopic
- Romosozumab
- Design
- Active-controlled RCT, 24 mo
- Relevance
- Important: one of several pillars.
- Source
- Saag KG, et al. N Engl J Med. 2017;377(15):1417-1427.doi 10.1056/NEJMoa1708322
Discussion & critique
Anabolic-then-antiresorptive sequence beats antiresorptive alone, but the CV signal restricts use in patients with recent MI or stroke.